Literature DB >> 10647992

CD40-CD40 ligand.

C van Kooten1, J Banchereau.   

Abstract

CD40 is a cell surface receptor that belongs to the tumor necrosis factor-R (TNF-R) family, and that was first identified and functionally characterized on B lymphocytes. Its critical role in T cell-dependent humoral immune responses was demonstrated by patients with the hyper-IgM syndrome, as well as by gene targeting in mice. However, in recent years it has become clear that CD40 is expressed much more broadly, including expression on monocytes, dendritic cells, endothelial cells, and epithelial cells. In addition, the CD40-ligand (CD40-L/CD154), a member of the TNF family, is also expressed more widely than activated CD4+ T cells only. Therefore it is now thought that CD40-CD40-L interactions play a more general role in immune regulation. Collectively these studies have culminated in pre-clinical and clinical studies that are in progress. This article reviews recent developments in this field of research, with main emphasis on (1) structure and expression of CD40 and its ligand; (2) CD40 signal transduction; (3) in vitro function of CD40 on different cell types; and (4) in vivo functions of CD40/CD40-L interactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647992     DOI: 10.1002/jlb.67.1.2

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  447 in total

1.  Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system.

Authors:  R P Phipps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  A novel helper role for CD4 T cells.

Authors:  J M den Haan; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

3.  CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex.

Authors:  A Kaykas; K Worringer; B Sugden
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

Review 4.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

5.  Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma.

Authors:  G Tsirakis; C A Pappa; F E Psarakis; M Fragioudaki; C Tsioutis; E Stavroulaki; A Boula; M G Alexandrakis
Journal:  Med Oncol       Date:  2012-03-09       Impact factor: 3.064

6.  Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human colonic fibroblasts.

Authors:  C M Gelbmann; S N Leeb; D Vogl; M Maendel; H Herfarth; J Schölmerich; W Falk; G Rogler
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

8.  TNF-alpha is crucial for the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice.

Authors:  Reiko Horai; Akiko Nakajima; Katsuyoshi Habiro; Motoko Kotani; Susumu Nakae; Taizo Matsuki; Aya Nambu; Shinobu Saijo; Hayato Kotaki; Katsuko Sudo; Akihiko Okahara; Hidetoshi Tanioka; Toshimi Ikuse; Naoto Ishii; Pamela L Schwartzberg; Ryo Abe; Yoichiro Iwakura
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Selective regulation of CD40 expression in murine dendritic cells by thiol antioxidants.

Authors:  Norifumi Iijima; Yoshiki Yanagawa; Kazuya Iwabuchi; Kazunori Onoé
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

10.  CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8(+) T cell frequency and patient survival.

Authors:  Jonathan M Weiss; W Gregory Alvord; Octavio A Quiñones; Jimmy K Stauffer; Robert H Wiltrout
Journal:  Hum Immunol       Date:  2014-05-04       Impact factor: 2.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.